Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

BioXcel Therapeutics (BTAI) Assets Average (2022 - 2025)

BioXcel Therapeutics (BTAI) has 4 years of Assets Average data on record, last reported at $35.3 million in Q3 2025.

  • For Q3 2025, Assets Average fell 38.26% year-over-year to $35.3 million; the TTM value through Sep 2025 reached $35.3 million, down 38.26%, while the annual FY2024 figure was $56.0 million, 59.92% down from the prior year.
  • Assets Average reached $35.3 million in Q3 2025 per BTAI's latest filing, up from $32.2 million in the prior quarter.
  • Across five years, Assets Average topped out at $246.5 million in Q3 2022 and bottomed at $32.2 million in Q2 2025.
  • Average Assets Average over 4 years is $115.8 million, with a median of $82.5 million recorded in 2023.
  • The widest YoY moves for Assets Average: up 30.28% in 2023, down 61.36% in 2023.
  • A 4-year view of Assets Average shows it stood at $225.3 million in 2022, then plummeted by 61.36% to $87.1 million in 2023, then crashed by 49.91% to $43.6 million in 2024, then decreased by 19.09% to $35.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Assets Average were $35.3 million in Q3 2025, $32.2 million in Q2 2025, and $38.5 million in Q1 2025.